Abstract: The disclosure provides a resin cleaning device and method. The resin cleaning device includes a control system, a treatment unit, a driving unit, and a feedback assembly. The treatment unit, the driving unit, and the feedback assembly are respectively in communication connection with the control system. The treatment unit is configured for treating a member-to-be-cleaned so as to reduce a viscosity of resin on the member-to-be-cleaned. The driving unit is configured for driving the member-to-be-cleaned to rotate. The feedback assembly is configured for acquiring a position signal of the member-to-be-cleaned and feeding the position signal back to the control system, such that the control system controls the treatment unit and the driving unit according to the position signal. Through the above manner, a more intelligent resin cleaning process with a better cleaning effect may be realized.

Abstract: A computerized simulation validating method for a full-scale distribution network single phase-to-ground fault test is implemented by simulating a full-scale test system with external quantities being controlled to be conformant and validating the full-scale distribution network single phase-to-ground fault test based on a conformance check result between the internal quantities of the field testing and the internal quantities of the simulation testing. The simulation validating method for a full-scale distribution network single phase-to-ground fault test improves normalization and conformance of the full-scale distribution network ground fault test. The computerized simulation validating system, apparatus, and medium for a full-scale distribution network single phase-to-ground fault test also achieve the benefits noted above.

Abstract: Systems and methods may generate code, for a model, with one or more service access points generated and at locations in the code based on an analysis of model constraints and deployment specifications (e.g., RTE specifications or OS specifications). The systems and methods may analyze the model and identify a functionality that needs an RTE service. The system and methods may receive deployment specifications. The systems and methods may generate code for the model, where an analysis of model constraints and the deployment specifications determine which service access points are generated and where in the code the service access points are located. In an embodiment, the code may be executed by different RTEs. In an embodiment, the systems and methods may determine, based on the analysis of the model constraints and the deployment specification, one or more admissible implementations for an RTE service that may be implemented in different ways.

Abstract: Systems and methods may generate code, for a model, with one or more service access points generated and at locations in the code based on an analysis of model constraints and deployment specifications (e.g., RTE specifications or OS specifications). The systems and methods may analyze the model and identify a functionality that needs an RTE service. The system and methods may receive deployment specifications. The systems and methods may generate code for the model, where an analysis of model constraints and the deployment specifications determine which service access points are generated and where in the code the service access points are located. In an embodiment, the code may be executed by different RTEs. In an embodiment, the systems and methods may determine, based on the analysis of the model constraints and the deployment specification, one or more admissible implementations for an RTE service that may be implemented in different ways.

Abstract: The present invention relates to a novel therapeutic drug for a neurodegenerative disease and an application thereof. Provided is a novel compound of formula (I). The compound can effectively facilitate the proliferation of neural stem cells in both in vitro and in vivo experiments and can be used as a treatment approach for facilitating neuroregeneration to fight against cognitive decline associated with aging or a neurodegenerative disease.

Abstract: A major hurdle in the treatment of cancer is chemoresistance induced under hypoxia that is characteristic of tumor microenvironment. Triptolide, a potent inhibitor of eukaryotic transcription, possesses potent antitumor activity. However, its clinical potential has been limited by toxicity and water solubility. To address those limitations of triptolide, the present disclosure designed and synthesized glucose-triptolide conjugates (glutriptolides) and demonstrated their antitumor activity in vitro and in vivo. The glutriptolides disclosed herein possess improved stability in human serum, greater selectivity towards cancer over normal cells and increased potency against cancer cells. Importantly, the glutriptolides are more potent against cancer cells under hypoxic conditions in contrast to existing cytotoxic drugs. These glutriptolides also exhibit sustained antitumor activity, prolonging survival in a prostate cancer metastasis animal model.

Abstract: The present invention relates to a novel compound for preventing or treating neurodegenerative diseases and use thereof. Provided is a novel compound of Formula (I). The compound can effectively promotes the proliferation of neural progenitor cells in both in vitro and in vivo experiments, and can serves as a treatment approach to promote nerve regeneration to fight against cognition impairment associated with aging and neurodegenerative diseases.

Abstract: Systems and methods may aggregate and organize implicit and explicit initialization, reset, and termination operations defined throughout the hierarchy of an executable. The systems and methods may analyze the model and identify implicit and explicit initialization, reset, and termination operations defined at various hierarchical levels. The systems and methods may aggregate the implicit and explicit initialization, reset, and termination operations into an initialize callable unit, a reset callable unit, and a termination callable unit. The systems and methods may apply optimizations to the callable units, and resolve conflicts. The systems and methods may define a single entry point for each of the initialize, reset, and termination callable units.

Abstract: Systems and methods decouple model components from a model execution style for which the model components are created, and the model components may be utilized in parent models having different execution styles. A model component may be partitioned into executable entities, and the entry points of the executable entities and their call styles may be identified. An adaptation layer that includes access points for the entry points may be constructed. The model component, including the adaptation layer, may be included in the model, and connection elements of the parent model may be connected to the access points of the adaptation layer. The execution call styles associated with the connection elements of the parent model may be bound to the execution call styles of the entry points as originally designed. The adaptation layer may manage translation of call styles and may coordinate scheduling of data communication with the model component.

Abstract: Systems and methods decouple model components from a model execution style for which the model components are created, and the model components may be utilized in parent models having different execution styles. A model component may be partitioned into executable entities, and the entry points of the executable entities and their call styles may be identified. An adaptation layer that includes access points for the entry points may be constructed. The model component, including the adaptation layer, may be included in the model, and connection elements of the parent model may be connected to the access points of the adaptation layer. The execution call styles associated with the connection elements of the parent model may be bound to the execution call styles of the entry points as originally designed. The adaptation layer may manage translation of call styles and may coordinate scheduling of data communication with the model component.

Abstract: Systems and methods may generate code, for a model, with one or more service access points generated and at locations in the code based on an analysis of model constraints and deployment specifications (e.g., RTE specifications or OS specifications). The systems and methods may analyze the model and identify a functionality that needs an RTE service. The system and methods may receive deployment specifications. The systems and methods may generate code for the model, where an analysis of model constraints and the deployment specifications determine which service access points are generated and where in the code the service access points are located. In an embodiment, the code may be executed by different RTEs. In an embodiment, the systems and methods may determine, based on the analysis of the model constraints and the deployment specification, one or more admissible implementations for an RTE service that may be implemented in different ways.

Abstract: Provided is the use of an aromatic ring drug in inhibiting a key transcription factor of malignant melanoma. In particular, provided is the use of a compound as represented by formula A, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition or preparation. The pharmaceutical composition or preparation is used for: (a) inhibiting a key transcriptional regulatory factor of malignant melanoma, namely MITF (Microphthalmia-associated Transcription Factor); (b) treating MITF-related diseases such as melanoma, pancreatic cancer, skin hypersensitivity and asthma; and (c) regulating physiological activities in which MITF is involved, such as skin whitening. In the formula, each group is as defined in the description.

Abstract: The present invention relates to a novel therapeutic drug for a neurodegenerative disease and an application thereof. Provided is a novel compound of formula (I). The compound can effectively facilitate the proliferation of neural stem cells in both in vitro and in vivo experiments and can be used as a treatment approach for facilitating neuroregeneration to fight against cognitive decline associated with aging or a neurodegenerative disease.

Abstract: Embodiments of the present disclosure relate to the field of computer technologies and, in particular, to an open-source-license analyzing method and apparatus, including: receiving a file-to-be-tested and a planning condition; detecting an open-source license involved in the file-to-be-tested; matching the detected open-source license with the planning condition to determine a first conflict between the detected open-source license and the planning condition; and generating a first risk assessment report based on the first conflict. The embodiments of the present disclosure are used to analyze and evaluate the risk of using open-source licenses.

Abstract: The present invention relates to a novel compound for preventing or treating neurodegenerative diseases and use thereof. Provided is a novel compound of Formula (I). The compound can effectively promotes the proliferation of neural progenitor cells in both in vitro and in vivo experiments, and can serves as a treatment approach to promote nerve regeneration to fight against cognition impairment associated with aging and neurodegenerative diseases.

Abstract: Provided are compounds generated by conjugation of triptolide with glucose to form glucose-triptolide conjugates, provides compounds with effective anti-proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.

Abstract: A method and apparatus for monitoring during dynamic processes that determines when effective measurements of thermal effusivity and/or thermal conductivity can be made during a portion of a cycle during a calibration phase, then measures thermal effusivity and/or thermal conductivity during a subsequent dynamic process in dependence upon the time delay value and the measurement duration value until a desired value is obtained. A sensor having a measurement period of between one to two seconds allows monitoring of materials during dynamic processes such as tumbling, blending, mixing, and rocking. For example, measurements can be made until a value indicative of a desired mixture condition is obtained.

Abstract: Disclosed are a retinoid compound, a preparation method therefor, intermediates thereof and an application thereof. The retinoid compound I of the present invention has a good tumor growth inhibition rate.

Abstract: Provided are compounds generated by conjugation of triptolide with glucose to form glucose-triptolide conjugates, provides compounds with effective anti-proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.

Abstract: Systems and methods may aggregate and organize implicit and explicit initialization, reset, and termination operations defined throughout the hierarchy of an executable. The systems and methods may analyze the model and identify implicit and explicit initialization, reset, and termination operations defined at various hierarchical levels. The systems and methods may aggregate the implicit and explicit initialization, reset, and termination operations into an initialize callable unit, a reset callable unit, and a termination callable unit. The systems and methods may apply optimizations to the callable units, and resolve conflicts. The systems and methods may define a single entry point for each of the initialize, reset, and termination callable units.